132 results about "Muscle disease" patented technology

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits activity of a disease allele associated with muscle disease. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

The invention provides an entropy-based muscle fatigue assessment method and application thereof, and particularly relates to the technical field of signal processing, and the method comprises the steps: firstly collecting a surface electromyogram (sEMG) signal, and carrying out the preprocessing; then, fractional calculus is combined with a fluctuation dispersion entropy (FDE) algorithm, and a multi-scale processing process is introduced, so that an RCMFFDE algorithm is innovatively proposed. Performing multi-scale analysis on the preprocessed sEMG signal by using the algorithm to generate a plurality of entropy curves; the entropy curve meeting the preset condition is selected as the final entropy curve, and the final entropy curve can accurately reflect the muscle fatigue state. According to the method, the muscle fatigue degree can be effectively and reliably evaluated, and the method has important kinematics and medical significance for preventing human body muscle diseases and sports injuries.

The present invention relates to a composition for preventing or treating muscle disease comprising an extract of Aralia Elata. The Aralia Elata extract of the present invention has the effect of improving grip strength, increasing muscle weight, and improving exercise performance.

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits activity of a disease allele associated with muscle disease. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

Provided herein are oligonucleotides, chimeric peptides, and peptide-oligonucleotide-conjugates, the chimeric peptides and peptide-oligonucleotide-conjugates comprising at least two cell-penetrating peptides, wherein at least one of the cell-penetrating peptides is an amphipathic peptide and at least one of the cell-penetrating peptides is an oligoarginine peptide. The oligoarginine peptide comprises the sequence [(RYzR)x] (SEQ ID NOs: 15-18), wherein R is arginine, Y is independently selected from aminohexanoic acid (X) or β-alanine (B). Also provided herein are methods of treating a muscle disease, a viral infection, or a bacterial infection in a subject in need thereof, comprising administering to the subject oligonucleotides, chimeric peptides, and peptide-oligonucleotide-conjugates comprising at least two cell-penetrating peptides, wherein at least one of the cell-penetrating peptides is an amphipathic peptide and at least one of the cell-penetrating peptides is an oligoarginine peptide described herein.

The present disclosure relates to microbiome compositions for improving muscle strength using a heat-treated fermentative culture complex of KM2 Phytobacterium plantarum. The composition according to the present disclosure increases the synthesis of myoprotein and exhibits an effect of inhibiting the degradation of myoprotein. Animal tests show effects of improving muscle strength and increasing leg muscle mass by increasing grip strength, travel distance and speed, and results of improving popliteal muscle strength and increasing muscle mass even in clinical tests. Furthermore, it has been found that beneficial bacteria are increased by an increase in the diversity of the gut microbial flora, which varies as muscle decreases, and an improvement in the microbial flora composition, while harmful bacteria are reduced. Therefore, the composition can be used as a composition for preventing, alleviating or treating muscle diseases and a composition for improving muscle strength or increasing muscle mass.

The present invention relates to the field of pharmaceuticals and health food technology, and specifically to a method for preparing and applying red date polysaccharides. The specific technical solution comprises the following steps: a method for preparing red date polysaccharides comprises concentrating jujubes with distilled water, removing proteins, and then precipitating with ethanol to obtain a primary ethanol precipitate containing polysaccharides; dialyzing the primary ethanol precipitate, and then precipitating with ethanol to obtain a secondary ethanol precipitate containing polysaccharides, which is then freeze-dried. The extracted red date polysaccharides can improve glucose utilization, increase GLUT4 protein expression, and prevent palmitate-induced insulin resistance and muscle damage in muscle cells, and can be used to prevent, improve, or treat anabolic or muscular diseases.

Provided herein are oligonucleotides, trimeric peptides, and peptide-oligonucleotide-conjugates. Also provided herein are methods of treating a muscle disease in a subject in need thereof, comprising administering to the subject oligonucleotides, trimeric peptides, and peptide-oligonucleotide-conjugates described herein.

The present disclosure relates to a composition for preventing or treating muscle disease, comprising CXCL14 as an active ingredient. According to the present disclosure, it was confirmed that CXCL14 increased muscle differentiation and synthesis, thereby increasing muscle mass. In addition, it was confirmed that in LPS-induced muscular atrophy or DEX-induced muscular dystrophy, CXCL14 inhibited muscle loss, increased the expression of muscle synthesis and differentiation factors, and inhibited the expression of muscle degradation proteins. In addition, it was confirmed that CXCL14 promoted muscle synthesis and differentiation and inhibited the muscle degradation even in vivo.

Recombinant myotropic AAV rh.74 capsids are described herein. In addition, plasmids, viral vectors, dual vector systems, cells, and compositions comprising or encoding such recombinant capsids are further described. Such recombinant polynucleotides, plasmids, viral vectors, dual vector systems, cells, and compositions may be used to treat muscle diseases or disorders, including muscular dystrophies and cardiomyopathies.

The invention features methods of treating a disease or condition associated with elevated activin signaling (e.g., a bone disease, pulmonary hypertension, fibrosis, a muscle disease, a metabolic disease, thrombocytopenia, or neutropenia) by administering to a human subject a polypeptide including an extracellular ActRIIB variant fused to an Fc domain in an amount of 1.5 mg / kg to 4.5 mg / kg at a frequency of once every 28 days.

The present invention relates to peptide modified AAV capsids with increased muscle transduction efficiency. The invention also relates to derived recombinant AAV vector particles packaging a gene of interest and their use in gene therapy, in particular for the treatment of muscle diseases.

The present invention relates to a method for improving muscle strength, and / or muscle mass by administering a composition containing as an active ingredient at least one selected from the group consisting of Akkermansia muciniphila cells, a culture thereof and a lysate thereof, and a method for preventing or treating muscle diseases where muscle strength and / or mass is weakened by sarcopenia, cachexia or muscle wasting.

The present invention relates to a composition for the improvement and treatment of muscle diseases and cachexia, wherein diflunisal has the effect of promoting the differentiation and proliferation of myogenic cells, and further has the effect of improving and treating cachexia induced by chronic diseases such as muscle diseases or cancer through effects such as increased muscle mass and recovery of muscle strength.

Treatments of neuromuscular conditions, activity-induced muscle damage, metabolic myopathies, and movement disorders with compositions comprising 2-((5-fluoropyridin-3-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl)pyridazin-3(2H)-one (Compound 1), as well as solid forms of Compound 1, and pharmaceutical compositions of Compound 1, and kits of Compound 1, are described herein.

It was confirmed that probiotic metabolites of the present invention protect muscle cells and promote differentiation of muscle fibers. In addition, it was confirmed in an animal model of muscle atrophy or sarcopenia induced by dexamethasone that probiotic metabolites increased muscle mass and muscle function, inhibited expression of factors associated with muscle degradation, and increased expression of factors associated with muscle synthesis and regeneration. It was confirmed that probiotic metabolites contribute to alleviation of muscle atrophy by regulating sugar, amino acid, and fatty acid metabolism altered by dexamethasone.

The disclosure relates to compositions and methods for enhancing asymmetric division of satellite cells and promoting muscle cell / tissue regeneration, for treatment of muscle tissue injuries and muscle diseases, including muscular dystrophies.

The invention relates to a peptide-modified AAV capsid with improved tropism, in particular increased muscle tropism and / or reduced liver tropism. The invention relates also to the derived recombinant AAV vector particle packaging a gene of interest, and its use in gene therapy, in particular for treating muscle diseases.

The present application relates to a peptide exhibiting muscle loss prevention and muscle mass promotion activities, and use thereof, and provides: a peptide consisting of an amino acid sequence of SEQ ID NO: 1; a pharmaceutical composition for preventing or treating a muscle disease, comprising the peptide as an active ingredient; and a food composition for preventing or ameliorating a muscle disease, comprising the peptide as an active ingredient.

Recombinant myotropic AAV rh.74 capsids are described herein. In addition, plasmids, viral vectors, dual vector systems, cells, and compositions comprising or encoding such recombinant capsids are further described. Such recombinant polynucleotides, plasmids, viral vectors, dual vector systems, cells, and compositions may be used to treat muscle diseases or disorders, including muscular dystrophies and cardiomyopathies.

Provided herein are oligonucleotides, peptides, and peptide-oligonucleotide-conjugates. Also provided herein are methods of treating a muscle disease, a viral infection, or a bacterial infection in a subject in need thereof, comprising administering to the subject oligonucleotides, peptides, and peptide-oligonucleotide-conjugates described herein.

The present invention relates to the effect of promoting muscle development and growth through inhibition of the expression of MRF4. According to the present invention, MRF4 isolated and identified from skeletal muscles of Nile tilapia showed a strong association with MyoG and MEF2 proteins, and the expression of MyoG and MEF2 was found to significantly increase when the MRF4 gene was disrupted through CRISPR / Cas9 gene editing, and thus the present invention has the effect of being able to be used for the promotion of muscle development or the treatment of muscle diseases through the inhibition of the MRF4 gene.

The present disclosure provides a method of treating muscle myopathy, including muscle dystrophies and cardiomyopathies, by administering stable, long-lasting vasoactive intestinal peptide therapeutic agents. These agents include one or more elastin-like peptides and can be administered at a low-dose.

The present invention relates to a composition for the prevention or treatment of muscle diseases comprising an extract of Aralia elata. The Aralia elata extract of the present invention has the effect of enhancing grip strength, increasing muscle weight, and improving exercise performance.

The present invention relates to a mechanism that enables persons with a muscular disease to open the door, which can be used in places where people with muscular diseases are present, such as hospitals, health centers or places that are publicly accessible in daily life, characterized in that it comprises a door handle (2) for opening the door (1), a connecting shaft (3) attached to the end of the door handle (2), a power storage device (4) located on the door (1) which contains a battery and a motor-driven roller, a motion sensor (5) arranged on the power storage device (4) which detects the human hand, a touch sensor (6) which is attached to the door handle (2) and detects when the door handle (2) is held, and a steel cable (7) of which one end is connected to the connecting shaft (3) and of which the other end is connected to the roller in the power storage device (4).

The present invention provides, in part, protein-drug conjugates comprising an anti-transferrin receptor (e.g., human transferrin receptor) antigen binding protein (e.g., scFv, Fab) conjugated to a molecular load (e.g., a polynucleotide, liposome, or lipid nanoparticle) for delivery of the molecular load to a target tissue (e.g., brain or muscle). Methods of treating various diseases or disorders, such as neurological or muscular diseases, with the conjugates are provided.

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits activity of a disease allele associated with muscle disease. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

The present disclosure relates to an albumin nanocomposite comprising a phytochemical and a composition for muscle disease comprising the same, and more specifically, to an albumin nanocomposite comprising a phytochemical that exhibits an effect of inhibiting muscle loss caused by oxidative stress or inflammatory response and promoting the differentiation of myoblasts into muscle cells. The albumin nanocomposite comprising the phytochemical effectively delivers the phytochemical by targeting immune cells that induce reactive oxygen species and inflammatory responses. Accordingly, by regulating muscle-loss signaling pathways induced by reactive oxygen species and inflammatory responses, the nanocomposite inhibits muscle cell atrophy and promotes differentiation. Therefore, a composition comprising the albumin nanocomposite comprising the phytochemical according to the present disclosure can be provided as a composition for improving, preventing, or treating muscle diseases.

Disclosed are 20-hydroxyecdysone and the derivatives thereof, intended for use in the treatment of a neuromuscular disease such as spinal muscular atrophy or amyotrophic lateral sclerosis, or more particularly in the treatment of a specific disorder of the motor neurons causing alterations in the muscular function occurring in the context of these neuromuscular diseases.

The invention discloses approaches to correct DUX-4 expression in a cell using novel miRNA molecules.